COMP <GO>
AMPH vs SNDX // GROSS PROFIT MARGIN
Amphastar Pharmaceuticals Inc. (NASDAQ) VS. Syndax Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: AMPH 6
— SNDX 2
■ METRIC PARITY
LAST: $27.03 (-2.49%) • MKT CAP: $1.15B
gross-margins
49.50%
LAST: $13.10 (-4.03%) • MKT CAP: $1.17B
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMPH VS. SNDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMPH | SNDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 49.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.00% | -35.00% | +44.00 | AMPH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 10.58% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 19.50% | -60.00% | +79.50 | AMPH | /operating-margins <GO> |
| Net Profit Margin | 13.60% | -60.00% | +73.60 | AMPH | /net-margins <GO> |
| Revenue Growth (YoY) | -1.70% | 180.00% | -181.70 | SNDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.47 | 0.20 | +2.27 | AMPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 3/9 | +4.00 | AMPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.4 | 34.3 | +23.10 | AMPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.9x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.15B | $1.17B | -$20.0M | SNDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMPH REV | SNDX REV | AMPH GROSS % | SNDX GROSS % | AMPH FCF | SNDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.9M | $172.4M | 49.5% | — | $121.2M | -$323.2M |
| FY 2024 | $732.0M | $23.7M | 51.1% | — | $172.3M | -$274.9M |
| FY 2023 | $644.4M | $643.9M | — | — | $183.5M | -$160.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMPH // BETA —
SNDX // BETA —